The experimental drug Bremelanotide (formerly PT-141) does not act on the vascular system like the former compounds but increases sexual desire and drive in male as well as female. It is applied as a nasal spray. Bremelanotide works by activating melanocortin receptors in the brain. It is currently in Phase IIb trials. super sales of viagra online Buy viagra online canada buy viagra c.o.d viagra pills sale online order order phentermine viagra viagra online canadian pharmacy buy viagra online viagra buy to viagra where viagra for sale viagra in canada viagra pills for sale viagra sample pack check buy viagra canadian pharmacy free viagra order online viagra online canadian pharmacy online viagra viagra The study authors focused on 12 patients who had been diagnosed with chronic obstructive pulmonary disease and were suspected of having PAH. Throughout the study, right heart blood pressure was tracked among all 12 patients by inserting a thin plastic tube into the pulmonary artery -- a procedure known as cardiac catheterization. Cardiac blood pressure was measured at rest and just after all the patients cycled for three minutes. discounted viagra for sale viagra online buy viagra viagra online viagra genericviagra online Yohimbine improves erections for a small percentage of men. It stimulates the parasympathetic nervous system, which is linked to erection, and may increase libido. It is necessary to take the medication for 6 to 8 weeks before determining whether it will work or not. Second, an undescended testicle is more likely to develop a tumor. Testicular cancer affects one of every 2,000 men with undescended testicles. This rate of testicular cancer is higher than the rate in men whose testicles have dropped naturally. When the testicle is inside the scrotum, a man can easily feel his testicles to check for a tumor, or he can be checked by his doctor. This way, any tumor can be found early, when the cancer is easier to cure. Forget Viagra! Sound waves can send your sex life into orbit best price viagra viagra
 
 
Show background image
Tuesday, 23 September 2014

Cool Pictures

Shirini Yazdi

Home  >  Media  >  News Release

Study sheds light on lung cancers that are undetected by radiograph

Vienna, Austria: New research has revealed why some lung cancers are undetected by radiograph and helped to identify the type of people who may be at risk of this form of the disease.

 

The findings will be presented today (Monday 3 September 2012) at the European Respiratory Society’s Annual Congress in Vienna.

 

 

 

 

There has been no significant reduction in lung cancer mortality rates in recent years. Chest radiographs can be used to screen for lung cancer. However, these aren’t always effective and it appears that some cancers are later diagnosed even though individuals have received a negative chest radiograph within the previous 12 months.

 

The reason for this could be due to human error with the cancer being missed on the review of the radiograph, due to the cancer being undetectable by this form of screening technique, or because the cancer developed so rapidly that it both initiates and becomes evident in the time interval between screening tests.

 

Little is known about this form of lung cancer that is not detected by screening chest radiograph, which is referred to as an interval cancer. To improve the understanding of this type of the disease, researchers aimed to analyse the type of people who developed this cancer and the characteristics of the disease.

 

The research used data from a national screening trial in the USA. It followed 77,445 participants who were screened at the start of the study and then annually for either 2 or 3 years depending on their smoking status.

 

A total of 450 people were diagnosed with lung cancer during the years of chest radiograph screening, of which 152 were initially not spotted by the radiograph. Out of this group, 35% of lung cancers not initially identified on the radiograph were spotted when it was re-reviewed. The remaining 65% of this group therefore had ‘true interval cancer’ which was not detected on the initial screening, or the second review.

 

The results revealed that these cancers were at a more advanced stage when diagnosed, were more often small cell lung cancers and less often adenocarcinoma. The analysis also showed that this type of cancer was more common among males and those with a history of smoking.

 

Lead author, Dr. Paul Kvale from the Henry Ford Hospital in the USA, said: “These findings have helped us to understand the characteristics of this type of lung cancer, pointing out features which make them different from lung cancers that can be detected by a chest x-ray screening programme. The results add to the evidence that a screening programme using x-rays is not suitable for lung cancer, as this this more aggressive form of the disease will be missed.

 

“By increasing our understanding of true interval cancers, we can help to improve screening techniques in the future.”

Notes to editors:

  • Abstract: LATE-BREAKING ABSTRACT: Interval lung cancers not detected on screening chest x-rays: How are they different?
  • Session: 201
  • Date and time: Monday 3 September, 08:30-10:30
  • Room: C1

Press Office at ERS Congress in Vienna (Saturday 1st September - Wednesday 5th September 2012):

Lauren Anderson: +43 6763315356   This e-mail address is being protected from spambots. You need JavaScript enabled to view it

David Sadler: +43 6767502294

Abstract Print Zone

Browse the electronic book online, print the selected pages or download the full abstract book.

Access it now